Marker Therapeutics inc   (MRKR)
Other Ticker:  
Price: $3.6900 $0.06 1.653%
Day's High: $3.74 Week Perf: -2.38 %
Day's Low: $ 3.57 30 Day Perf: -20.47 %
Volume (M): 11 52 Wk High: $ 9.68
Volume (M$): $ 42 52 Wk Avg: $3.55
Open: $3.63 52 Wk Low: $0.67

 Market Capitalization (Millions $) 33
 Shares Outstanding (Millions) 9
 Employees -
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Marker Therapeutics Inc
Marker Therapeutics Inc. is a clinical-stage biotechnology company that specializes in the development and commercialization of immunotherapies for the treatment of various cancers. The company's patented MultiTAA T-cell therapy technology platform is designed to stimulate the patient's own immune system to target and destroy cancer cells. Marker Therapeutics aims to improve patient outcomes by utilizing personalized immunotherapies that have the potential to be more effective and have fewer side effects than traditional cancer treatments.

   Company Address: 9350 Kirby Drive, Suite 300 Houston 77054 TX
   Company Phone Number: 400-6400   Stock Exchange / Ticker: NASDAQ MRKR
   MRKR is expected to report next financial results on March 21, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Marker Therapeutics Earns Key Approval for MT-601 Under the New Name, Neldaleucel, Amid Financial Setbacks

Published Mon, Jan 22 2024 12:30 PM UTC

HOUSTON, Jan. 22, 2024. Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company, has achieved a significant scientific milestone, even as it contends with financial setbacks. The advanced biotech firm, dedicated to developing next-generation T cell-based immunotherapies, has announced that its leading product candidate has received crucial approval...

Product Service News

Traversing Bumpy Financial Terrain, Marker Therapeutics Eyes Revolutionary Cancer Treatments with MT-601.

Published Mon, Jan 8 2024 1:25 PM UTC

Marker Therapeutics, a leading bio-pharmaceutical firm, recently announced vital updates and strategic prioritization of its clinical programs with concentrated focus on MT-601 in patients diagnosed with lymphoma. This move is prompted by a series of significant advancements as well as the necessity to tap into promising therapeutic areas that embody the potential to oversha...

Clinical Study

Marker Therapeutics' MT-601: A Ray of Hope Amidst Revenue Challenges

Published Mon, Dec 11 2023 12:01 PM UTC

In a significant breakthrough for the field of immunotherapy, Marker Therapeutics Inc. recently announced a sustained complete response in the first lymphoma patient treated with MT-601 following a relapse from CAR T cell therapy. This milestone achievement brings renewed hope for patients facing relapses and underscores the potential of Marker Therapeutics' innova...

Marker Therapeutics Inc

Title: Major Pharmaceutical Preparations Company Witnesses Escalating Losses in Fiscal Period Ending September 30, 2023

Marker Therapeutics Inc. is facing a catastrophic fiscal period ending September 30, 2023, as the company witnessed a staggering decline in revenue by -93.478% to a mere $0.26 million. Furthermore, the net deficit per share has expanded to $-0.34, indicating a significant deterioration from the same quarter of the previous year. Even when compared to the preceding quarter, where the net deficit per share stood at $0.29, Marker Therapeutics Inc. experienced a massive drop in revenue by -66.223% from $0.76 million.
The distressing financial results of Marker Therapeutics Inc. continue to heighten as they reported a net loss of $-2.982 million in the fiscal period ending September 30, 2023, compared to a deficit of $-6.920 million during the same quarter a year ago. This consistent decline in financial performance raises serious concerns about the company's ability to sustain its operations and meet its financial obligations.

Marker Therapeutics Inc

Marker Therapeutics Inc sees remarkable turnaround with improved profitability and positive earnings per share

Marker Therapeutics Inc, a significant player in the pharmaceutical preparations industry, recently reported its financial results for the April to June 30, 2023 time period. These results highlight a remarkable turnaround for the company, with improved profitability, positive earnings per share (EPS), and substantial reductions in prior losses. However, there are a few areas of concern, including a decline in revenue and fluctuating accounts receivable. With these factors in mind, let us explore the potential impact these results may have on the future of Marker Therapeutics.
1. Profitability Flips:
Marker Therapeutics witnessed a significant improvement in profitability during the April to June 30, 2023 period. The company achieved an EPS of $0.29 per share, a substantial growth from the previous year's EPS of -$0.11 per share. Additionally, EPS turned positive from the preceding quarter's -$0.57 per share. This shift indicates a proactive strategy by the management, resulting in enhanced financial performance.


Marker Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com